NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus
NCCN has added everolimus (Afinitor®, Novartis) to the NCCN Guidelines for Kidney Cancer as a recommended treatment for patients with renal cell carcinoma whose disease has progressed after treatment with kinase inhibitors. This recommendation comes on the heels of the March 30, 2009 FDA approval of everolimus based upon results of a clinical trial which showed that the therapy significantly extended progression-free survival in a specific group of patients.
April 20, 2009
FORT WASHINGTON,...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology